TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06439147

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: U shaped capsular incision during capsulorrhaphy
Description: Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip,Incision is done with its base proximally. The transverse limb is 1 cm proximal to femoral neck base

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-shaped capsular incision diuring capsulorraphy
Description: Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip done by two incisions: Vertical limb parallel to femoral neck axis and a transverse one parallel to the inguinal ligament resulting into two flabs.
Study: NCT06129825

Intervention type: OTHER
Intervention: Prospective
Description: Single arm, healthy adult volunteers for blood donation.
Study: NCT06456905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants in the contingent group will be rewarded on an incrementally increasing scale for submitting consecutive breathalyzer samples that are 0.00%. For every day this target is met, the participant will receive an increase in reward until a daily cap is reached. If a day contains at least one sample where the target is not met, the participant will not be paid for that day, and the amount will reset. The participant will have the opportunity to earn on this scale throughout the duration of the study.
Study: NCT04673942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdAPT-001
Description: Oncolytic virus administered by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdAPT-001
Description: Oncolytic virus administered by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdAPT-001
Description: Oncolytic virus administered by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdAPT-001
Description: Oncolytic virus administered by intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor, Immune
Description: Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor, Immune
Description: Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
Study: NCT02864888

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Children with a diffuse, intrinsic brain stem glioma will receive radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Children with a diffuse, intrinsic brain stem glioma will receive radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atengenal
Description: Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astugenal
Description: Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
Study: NCT06453941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion)
Description: Yizhi Baduanjin (Eight Pieces of Brocades for Mental Health Promotion) is a newly compiled routine developed on the foundation of the traditional Baduanjin (Eight Pieces of Brocades), which is a traditional Chinese medical health exercise consisted of eight movements to be practiced by oneself.
Study: NCT04473066

Intervention type: PROCEDURE
Intervention: Adenotonsillectomoy +/- turbinate reduction
Description: Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
Study: NCT05656872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse Abdominis Plane Block
Description: Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal-iliohypogastric block
Description: Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
Study: NCT05790551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Addinex
Description: Medication dispensing system for Suboxone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Addinex
Description: Medication dispensing system for Suboxone
Study: NCT06484686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine
Description: lyophilized powder, subcutaneous injection
Study: NCT06252311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Breastfeeding Programme
Description: Mindfulness-Based Breastfeeding Programme will consist of structure and anatomy of the breast and milk production, breast milk content, benefits of breast milk, breast care, frequency and duration of breastfeeding, correct and comfortable position for breastfeeding, effects of stress on lactation hormones and milk production, World Health Organization guidelines on duration and continuity of breastfeeding, time to start complementary feeding general information on recommendations, General information about breastfeeding with awareness, mentioning its purpose and programme flow, and it includes formal and informal practices such as breathing awareness exercises, noticing the autopilot, lying/sitting meditation, body scanning exercises and mindful breastfeeding practice.
Study: NCT05516836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent exercise program
Description: Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program
Description: Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-health primary care rehabilitation program
Description: A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence.
Study: NCT06557434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRIA
Description: The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.
Study: NCT04967157

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cognizin®
Description: Oral
Study: NCT06557785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505M5 N197D mRNA-gp160
Description: To be administered intramuscularly as a split dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505M5 N197D mRNA-gp160
Description: To be administered intramuscularly as a split dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505M5 N197D mRNA-gp160
Description: To be administered intramuscularly as a split dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505M5 N197D mRNA-gp160
Description: To be administered intramuscularly as a split dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF mRNA-gp160
Description: To be administered intramuscularly as a split dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF mRNA-gp160
Description: To be administered intramuscularly as a split dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF mRNA-gp160
Description: To be administered intramuscularly as a split dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF mRNA-gp160
Description: To be administered intramuscularly as a split dose
Study: NCT06343636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG-3927
Description: Dose Escalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose Escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG-3927
Description: One Dose Level
Study: NCT04532424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.
Study: NCT05650567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049 high dose
Description: Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049 high dose
Description: Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks.
Study: NCT03994887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
Study: NCT05650567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.
Study: NCT04832802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS
Description: ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IPS
Description: IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
Study: NCT04999215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-choline intravenous injection
Description: Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
Study: NCT05882734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
Study: NCT05629065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Nudge Email
Description: -Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Nudge Email
Description: -Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Nudge Letter and Share questionaire
Description: Involves patient nudge consists of a letter and SHARE questionnaire~- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Nudge Letter and Share questionaire
Description: Involves patient nudge consists of a letter and SHARE questionnaire~- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit.
Study: NCT05538312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vepdegestrant
Description: Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
Study: NCT06440967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamoxifen
Description: oral
Study: NCT05882734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.
Study: NCT06440967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aromatase inhibitor
Description: oral
Study: NCT06057935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Possible substitution with carboplatin based on clinician discretion
Study: NCT06097533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabisextrakt Avextra 10/10 Lösung
Description: medical cannabinoids

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabisextrakt Avextra 10/10 Lösung
Description: medical cannabinoids
Study: NCT05787587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE-161
Description: Oral Medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE-161
Description: Oral Medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE-161
Description: Oral Medication
Study: NCT06215040

Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancratography
Description: common bile duct stone removal
Study: NCT05721326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential EHR Communications
Description: The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
Study: NCT06354309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality game
Description: Pre and post control study after use virtual reality game
Study: NCT06638151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin + clopidogrel
Description: Enrolled patients with acute ischemic stroke will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2-day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg once daily alone
Study: NCT05875168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3939a
Description: One IV infusion Q3W on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3939a
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Study: NCT06003426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days
Study: NCT05702853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Injection
Description: 30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
Study: NCT06003426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986278 Placebo
Description: Specified dose on specified days
Study: NCT06128200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEUROMARK System
Description: The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NEUROMARK System
Description: Sham ablation procedure using the NEUROMARK System
Study: NCT05702853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Injection
Description: 30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34t metabolically programmed CAR transduced T-cells
Description: Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34t metabolically programmed CAR transduced T-cells
Description: Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34t metabolically programmed CAR transduced T-cells
Description: Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
Study: NCT06640725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab administration at 10mg/kg
Description: Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Avelumab 10 mg/kg every 2 weeks (±3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux)
Description: Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\])
Study: NCT05189925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp91 Grans
Description: Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp91 Grans
Description: Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.
Study: NCT05276973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy